

Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

<https://marketpublishers.com/r/GE998B857A8EN.html>

Date: September 2018

Pages: 165

Price: US\$ 4,900.00 (Single User License)

ID: GE998B857A8EN

Abstracts

Description

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth \$1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to \$2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.

Global microbiome market, global breakdown, application breakdown and leading market players

Detailed account of the microbiome industry market by geography, indication and company profiles

Profiles, pipeline products, financial analysis and business strategy of the major companies in this space

Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics

Insight into the challenges faced by stakeholders

Insight into the biobanking industry globally and its impact on the overall market

Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota

Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective

SWOT analysis of the global market

Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW

Executive Summary

The global microbiome therapeutic and diagnostic market is worth \$1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to \$2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. Therefore, the global microbiome therapeutics market is worth \$x billion in 2018, compared to \$x billion in the diagnostic space. By 2023, therapeutics will grow to \$x billion, and diagnostics will grow to \$x billion globally. Growth will certainly depend on a number of factors including positive results from clinical trials, continued investment and regulatory strategies.

Our analysis indicates that North America holds the lions share of the microbiome therapeutic and diagnostic market in 2018 at \$x million. This compares to \$x million in Europe, \$x million in Asia Pacific, and \$x million in the Middle East. By 2023, North America will continue to dominate the market, with a revenue of \$x billion, compared to \$x million in Europe, \$x million in Asia Pacific, and \$x million in the Middle East.

Market Applications & Therapeutic Areas

Our Analysis has identified six key therapeutic areas that the microbiome therapeutic and diagnostic market is sub-divided into, namely:

Gastrointestinal

Metabolic

Cancer

Neurological

Autoimmune

Skin Disorders

The gastrointestinal therapeutic market is the most dominant, demanding \$x million in revenue in 2018, which will rise to \$x million by 2023. This is mainly due to disease states such as Clostridium difficile infection, Crohn's disease, ulcerative colitis and gastroenteritis. As mentioned throughout our report, this is the key area for active clinical trials and impending drug launches. This area currently demands x% of the overall market and will tend to dominate this space for the foreseeable future. The gastrointestinal diagnostic market is currently worth \$x million and is set to reach \$x million by 2023.

Second to this, metabolic therapeutics has a x% market share and in 2018 is worth \$x million, and will hit \$x million by 2023. The corresponding diagnostic market is currently worth about \$x million, which will increase to \$x million by 2023. The main indications within this field include diabetes, obesity and non alcoholic liver disease.

The microbiome cancer therapeutics market is currently worth \$x million, or x% of the total market. Our analysis indicate that this will rise to \$x million in 2023 and remain in third place behind metabolic and gastrointestinal disorders. The corresponding diagnostic submarket is currently worth \$x million, which is set to grow to \$x million in 2023.

The neurological market includes dominant indications such as Alzheimer's, Parkinson's, depression, anxiety disorders and autism. In 2018, the therapeutic submarket is worth \$x million, with a x% share in the total market. This is set to increase

to \$x million by 2023. The neurological microbiome diagnostic market is currently worth \$x million, which will increase to over \$x million by 2023.

Autoimmune disorders such as multiple sclerosis currently demand \$x million in the microbiome therapeutics market, which will increase to \$x million by 2023. The smaller diagnostic market is currently worth \$x million, and will grow to \$x million in 2023.

Skin disorders such as acne, dermatitis and psoriasis currently have about x% share in the overall microbiome market, and the therapeutics area is worth \$x million in 2018. This is set to rise to \$x million by 2023. The corresponding diagnostics area will hit \$x million in 2023, from \$x million in 2018.

Competitive Landscape

The microbiome field is highly competitive, especially within the inflammatory bowel disease and *Clostridium difficile* infection therapeutic markets. A wide range of big pharma, biotech, early-stage companies, academic institutions, government agencies and other public and private research organizations are involved in this space. The main therapeutic competitors within the microbiome industry are as follows:

Johnson & Johnson

Novartis International

Abbvie

Takeda

Merck & Co.,

Bristol Myers Squibb

Pfizer

Seres Therapeutics

Vedanta Biosciences

Finch Therapeutics

Enterome Bioscience

Second Genome

More specifically, companies involved in C. difficile infection include Actelion Pharmaceutical, Assembly Biosciences, AzurRx, Da Volterra, Pfizer, Merck, Merus, Rebiotix, Sanofi, Seres Therapeutics, Synthetic Biologics and Summit Therapeutics. Companies within the IBS-Constipation market include Ardelyx, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Synthetic Biologics and Takeda. Within the pertussis market GlaxoSmithKline, Mitsubishi Tanabe Pharma Corporation and Sanofi are major players. BioMarin Pharmaceutical, Synthetic Biologics, Codexis and Synlogic are involved in the PKU market. Within the diagnostic sub-market, the following are the main players:

Metabionics - Colon Polyp and Colon Cancer Test

Origin Sciences - Colorectal Cancer (CRC) Test

Enterome/AbbVie - IBD110

Key Questions Answered

What are the Main Microbiome Therapeutics in the Pipeline?

What are the Main Microbiome Diagnostics in the Pipeline?

What Key Biologics are in the Pipeline?

How Many Human Therapeutic and Diagnostic Microbiome Products are in the Pipeline?

What is the Human Therapeutic Pipeline like by Drug, Company and Stage of Development?

What Microbiome Therapeutics are in the Clostridium Difficile Infection Pipeline?

Who are the Major Players in the Therapeutic and Diagnostic Spaces?

What will the Microbiome Therapeutic Market be Worth in 2023?

What will the Microbiome Therapeutic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?

What will the Microbiome Diagnostic Market be Worth in 2023?

What will the Microbiome Diagnostic Sub-Markets (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin) be Worth in 2023?

What are the Main Drivers, Threats and Opportunities of these Markets?

What were the Most Influential Market Deals to Date?

How Much Venture Capital has Been Invested in the Microbiome Industry?

What Major Microbiome Companies have Received Investment?

What Microbiota are Associated with Cancer Development?

How does Gut Dysbiosis influence the Host Inflammatory Response?

Is there an Association Between the Development of Diabetes and Our Microbiota?

How does Clostridium difficile Infection Impact the Microbiome?

What Host-Microbe Interactions Occur During the Pathogenesis of Dental Caries?

During Cirrhosis of the Liver, What Brain Dysfunction Occurs Due to Gut Dysbiosis?

What are the Main Therapeutic Intervention Strategies for Microbiome Dysbiosis

What Safety Requirements are Needed for Microbiome Therapeutics?

What Clinical Trials are Investigating Probiotics and Obesity?

What Clinical Trials are Investigating Probiotics and Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease?

What Clinical Trials are Investigating Probiotics and Irritable Bowel Syndrome?

What Clinical Trials are Investigating Probiotics and Obesity?

How Has the Human Microbiome Project Investigated IBD, Prediabetes and Pregnancy?

How does the Human Microbiome Differ Between Geographical Areas and Bodily Locations?

Contents

CHAPTER 1 EXECUTIVE SUMMARY

- 1.1 Synopsis
- 1.2 Objective of Report
- 1.3 Executive Summary
- 1.4 Key Questions Answered
- 1.5 Data Sources & Methodology

CHAPTER 2 MICROBIOME OVERVIEW

- 2.1 Microbiome Overview
- 2.2 Human Microbiome in Health and Disease
 - 2.2.1 Cancer
 - 2.2.2 Obesity
 - 2.2.3 Microbiota Metabolism
 - 2.2.3 Type 2 Diabetes Mellitus
 - 2.2.4 Ulcerative Colitis and Crohn's Disease
 - 2.2.5 Clostridium Difficile Infection
 - 2.2.6 Lactose Intolerance
 - 2.2.7 CNS Disorders (gut brain axis)
 - 2.2.8 Dental caries
 - 2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
 - 2.2.10 Skin Diseases
 - 2.2.11 Hyperoxaluria
 - 2.2.12 Urea Cycle Disorder
 - 2.2.13 Celiac Disease
 - 2.2.14 Non-alcoholic Steatohepatitis (NASH)
 - 2.2.15 Hepatic Encephalopathy
- 2.3 Types of Microbiome therapeutics
 - 2.3.1 Prebiotics
 - 2.3.2 Live BioTherapeutic Agents (Probiotics)
 - 2.3.3 Fecal Microbiota Transplantation (FMT)
 - 2.3.4 Small Molecules
- 2.4 Advances in Microbiome Research
 - 2.4.1 MetaHIT Consortium
 - 2.4.2 Human Microbiome Project
 - 2.4.3 Functional Metagenomics

- 2.4.4 Microbiome Metabolomics
- 2.4.5 Identifying Microbiome Targets – Enterome EB8018 Case Study
- 2.5 Geographical Variation of Microbiome Composition

CHAPTER 3 HUMAN THERAPEUTIC AND DIAGNOSTIC PIPELINE ANALYSIS

- 3.0 Synopsis
- 3.1 Clostridium Difficile
 - 3.1.1 SER-109 Seres Therapeutics
 - 3.1.2 SER-262 Seres Therapeutics
 - 3.1.3 RBX2660 Rebiotix
 - 3.1.4 VE303 Vedanta Biosciences
 - 3.1.5 IMM-529 Immuron
 - 3.1.6 MET-2 NuBiyota
 - 3.1.7 CP101 Finch Therapeutics
 - 3.1.8 ABI-M101 Assembly Biosciences
 - 3.1.9 CBM-588 Osel
 - 3.1.10 SYN-004 Synthetic Biologics
 - 3.1.11 SYN-006 Synthetic Biologics
- 3.2 Ulcerative Colitis
 - 3.2.1 FIN-524 Finch Therapeutics
 - 3.2.2 SER-287 Seres Therapeutics
 - 3.2.3 ABI-M201 Assembly Biosciences
- 3.3 Crohn's Disease
 - 3.3.1 ABI-M301 Assembly Biosciences
 - 3.3.2 Thetanix 4D Pharma
- 3.4 Inflammatory Bowel Disease
 - 3.4.1 SER-301 Seres Therapeutics
 - 3.4.2 SGM-1019 Second Genome
 - 3.4.3 Blautix 4D Pharma
 - 3.4.4 SG-2-0776 Second Genome
 - 3.4.5 IBD110 – Enterome/AbbVie
- 3.5 Immuno-Oncology
 - 3.5.1 SER-401 Seres Therapeutics
 - 3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
 - 3.5.3 Colorectal Cancer (CRC) Test – Origin Sciences
- 3.6 Graft Versus Host Disease
 - 3.6.1 SER-155 Seres Therapeutics
- 3.7 Urinary Tract Infections

- 3.7.1 LACTIN-V Osel
- 3.8 Liver Disease
 - 3.8.1 SGM-1019 Second Genome
- 3.9 Phenylketoneuria
 - 3.9.1 SYN1020 Synlogic
 - 3.9.2 SYN1618 Synlogic

CHAPTER 4 MARKET ANALYSIS & FORECAST TO 2023

- 4.0 Synopsis
- 4.1 Market Applications
 - 4.1.1 Clostridium Difficile Infection
 - 4.1.2 Inflammatory Bowel Disease
 - 4.1.3 Ulcerative Colitis
 - 4.1.4 Crohn's Disease
 - 4.1.5 Liver Disease
 - 4.1.6 Immuno-Oncology
 - 4.1.7 Phenylketonuria
- 4.2 Competitive Landscape
- 4.3 Market Forecast to 2023
 - 4.3.1 Synopsis
 - 4.3.2 Primary Research, Clinical Trial and Pipeline Trends and Analysis
 - 4.3.3 Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
 - 4.3.4 Geographical Breakdown Analysis and Forecast to 2023
 - 4.3.5 Therapeutic and Diagnostic Submarket Breakdown By Indication

CHAPTER 5 MARKET DRIVERS, TRENDS & SWOT ANALYSIS

- 5.1 Market Drivers & Trends
- 5.2 Market Threats & Challenges
- 5.3 Market Opportunities

CHAPTER 6 INVESTMENT AND MARKET DEALS

- 6.1 Public and Private Funding in the Microbiome Space
- 6.2 Current Market Deals

CHAPTER 7 VENTURE CAPITAL AND THE MICROBIOME

7.0 Synopsis

7.1 How Much Investment Has been Poured into the Microbiome Space in Recent Years?

7.2 What Investment Firms are Interested in the Microbiome Space?

7.3 What Companies are Receiving Funding?

7.4 What Funding Cycles are Emerging in this Space?

CHAPTER 8 MAJOR PLAYERS AND COMPANY PROFILES

8.1 4D Pharma

8.2 Abbvie

8.3 Allergan

8.4 Assembly Biosciences

8.5 Bristol Myers Squibb

8.6 C3J Therapeutics

8.7 Da Volterra

8.8 Enterome

8.9 Finch Therapeutics

8.10 Immuron

8.11 Matrisys Bioscience

8.12 Merck

8.13 Osel

8.14 Pfizer

8.15 Quorum Innovations

8.16 Rebiotix

8.17 Second Genome

8.18 Seres Therapeutics

8.19 Synlogic

8.20 Synthetic Biologics

8.21 Takeda

8.22 Vedanta Biosciences

List Of Exhibits

LIST OF EXHIBITS

Exhibit 2.1: Microbiota Associated with Cancer Development

Exhibit 2.2: Gut Microbiota Dysbiosis and the Development of Inflammatory Immune Responses

Exhibit 2.3: Microbiota Metabolites

Exhibit 2.4: Association of Diet and Microbiota with Development of Diabetes

Exhibit 2.5: Dysbiotic Microbiota and Development of the Inflammatory Response Following *C. difficile* Infection

Exhibit 2.6: Host-Microbe Interactions During the Pathogenesis of Dental Caries

Exhibit 2.7: Brain Dysfunction Due to Altered Microbiota in Cirrhosis

Exhibit 2.8: Therapeutic Intervention Strategies for Microbiome Dysbiosis

Exhibit 2.9: Characteristics of Prebiotics and Probiotics

Exhibit 2.10: Probiotic Safety, Functional and Technological Usability Requirements

Exhibit 2.11: Probiotics Action within the Human Gut

Exhibit 2.12: Clinical Trials Investigating Probiotics and Obesity

Exhibit 2.13: Clinical Trials on Probiotics, Type 2 Diabetes & Non-Alcoholic Fatty Liver Disease

Exhibit 2.14: Clinical Trials Investigating Probiotics and Irritable Bowel Syndrome

Exhibit 2.15: Timeline of Fecal Microbiota Transplantation

Exhibit 2.16: Small Molecules Derived from the Human Microbiota

Exhibit 2.17: Gut IBD Microbiome Analysis by the Human Microbiome Project

Exhibit 2.18: Prediabetes Microbiome Analysis by the Human Microbiome Project

Exhibit 2.19: Pregnancy and Neonate Microbiome Analysis by the Human Microbiome Project

Exhibit 2.20: Metagenomic Analysis of the Gut Microbiome

Exhibit 2.21: Microbiome Metabolomic Applications in Health and Disease

Exhibit 2.22: Metabolites Associated with Microbial and Host metabolism

Exhibit 2.23: Enterome Platform to Study Gut Microbiome in IBD

Exhibit 2.24: Enterome EB8018 Anti-FimH Molecule for the Treatment of IBD

Exhibit 2.25: Global Microbiome Diversity by Geography and Body Area

Exhibit 3.1: Human Therapeutics Microbiome Product Pipeline

Exhibit 3.2: Number of Human Therapeutic and Diagnostic Microbiome Pipeline Products, Globally

Exhibit 3.3: Human Microbiome Therapeutics Pipeline by Drug, Company, Development Stage and Indication

Exhibit 3.4: IMM-529 by Immuron Mechanism of Action

- Exhibit 4.1: Microbiome Therapeutics in Clostridium Difficile Infection
- Exhibit 4.2.: Microbiome Therapeutic and Diagnostic Major Player Market Share Forecast 2023
- Exhibit 4.3: Percentage of PubMed Citations by Microbiome Disease Application
- Exhibit 4.4: Percentage of Clinical Trials by Microbiome Disease Application
- Exhibit 4.5: Global Therapeutic and Diagnostic Microbiome Market Revenue Forecast 2018-2023
- Exhibit 4.6: Current Global Therapeutic and Diagnostic Market Share of Microbiome Market
- Exhibit 4.7: Global Therapeutic Microbiome Market Revenue Forecast 2018-2023
- Exhibit 4.8: Global Diagnostic Microbiome Market Revenue Forecast 2018-2023
- Exhibit 4.9: Geographical Microbiome Market Analysis 2018
- Exhibit 4.10: Geographical Microbiome Market Forecast 2023
- Exhibit 4.11: Gastrointestinal Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.12: Metabolic Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.13: Cancer Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.14: Neurological Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.15: Autoimmune Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.16: Skin Microbiome Therapeutic Market Forecast to 2023
- Exhibit 4.17: Gastrointestinal Microbiome Diagnostic Market Forecast to 2023
- Exhibit 4.18: Metabolic Microbiome Diagnostic Market Forecast to 2023
- Exhibit 4.19: Cancer Microbiome Diagnostic Market Forecast to 2023
- Exhibit 4.20: Neurological Microbiome Diagnostic Market Forecast to 2023
- Exhibit 4.21: Autoimmune Microbiome Diagnostic Market Forecast to 2023
- Exhibit 4.22: Skin Disorders Microbiome Diagnostic Market Forecast to 2023
- Exhibit 5.1: Drivers of the Microbiome Market
- Exhibit 5.2: Threats and Challenges of the Microbiome Market
- Exhibit 6.1: Current Market Deals in the Microbiome Space
- Exhibit 7.1: Total Venture Capital Invested in the Microbiome Space, 2013-2017
- Exhibit 7.2: Venture Capital Invested in the Microbiome Space by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2013-2017
- Exhibit 7.3: Major Investment Firms and Investment Numbers in the Microbiome Industry by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2010-2017
- Exhibit 7.4: Major Microbiome Companies and Investment Received to 2017
- Exhibit 7.5: Microbiome Industry Investors and Companies
- Exhibit 7.6: Major Microbiome Companies and Investment Received to 2017
- Exhibit 7.7: Therapeutic and Diagnostic Microbiome Investments by Funding Cycle 2010-2017
- Exhibit 8.1: 4D Pharma Development Pipeline Product Portfolio

- Exhibit 8.2: Assembly Biosciences Pipeline Product Pipeline
- Exhibit 8.3: Assembly BioSciences R&D Expenditure 2015-2017
- Exhibit 8.4: C3J Therapeutics STAMP Platform
- Exhibit 8.5: C3J Therapeutics Product Pipeline
- Exhibit 8.6: Da Volterra Product Pipeline Portfolio
- Exhibit 8.7: Enterome Drug Discovery Platform
- Exhibit 8.8: Enterome Product Pipeline
- Exhibit 8.9: Osel Pipeline Product Portfolio by Clinical Stage
- Exhibit 8.10: Quorum Innovations Product Pipeline Portfolio
- Exhibit 8.11: Microbiota Restoration Therapy Application Areas
- Exhibit 8.12: Second Genome Product Pipeline Portfolio
- Exhibit 8.13: Seres Therapeutics Product Pipeline
- Exhibit 8.14: Seres Therapeutics R&D Expenditure 2015-2017
- Exhibit 8.15: Synlogic Product Pipeline Portfolio
- Exhibit 8.16: Synthetic Biologics Product Pipeline
- Exhibit 8.17: Synthetic Biologics R&D Expenditure 2015-2017

I would like to order

Product name: Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

Product link: <https://marketpublishers.com/r/GE998B857A8EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE998B857A8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970